16:12 EST Cerus (CERS) raises FY25 product revenue view to $202M-$204M from $200M-$203M
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERS:
- CERS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cerus Corporation’s New Study on Trauma Hemorrhage Treatment: A Potential Game Changer?
- Cerus Corporation: Buy Rating Highlighted by Growth Potential and Undervaluation
- Cerus Corporation’s New Study on Pathogen-Reduced RBCs: A Potential Game-Changer for Sickle Cell Disease
- Cerus Corporation’s New Study on INTERCEPT RBCs: Potential Market Impact